Novo CEO says obesity market won't be winner-take-all battle with Lilly

Novo Nordisk CEO Mike Doustdar said investors are underestimating the demand for differentiation among obesity drugs, ‌and that new treatment options like pills will keep it from becoming a winner-tak...

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。